Payer-Pharma Collaboration Through Value-Based Contracts is Set to Accelerate

 

Scientific advancements have created miracle cures for seemingly intractable diseases—along with astronomic price tags. Now, a new trend is exciting pharma, payers, physicians, patients and even analysts: linking drug reimbursement to patient outcomes. As this payment structure expands beyond chronic disease into specialty disease, how do you decide what a drug is worth?

In this article, Precision for Value’s chief medical officer Dominic Galante, parses the options.

Click here to read the full article. 

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.